2019 American Transplant Congress
Apixaban Therapy Is Safe And Effective In Most Organ Transplant Populations
University of Virginia Health System, Charlottesville, VA
*Purpose: The bleed rates from the apixaban pivotal trial were 12.1% for non-major and 3.8% major bleeds. However outcomes in transplant recipients are less defined,…2019 American Transplant Congress
Anti-Xa Level Monitoring for Treatment Dose Enoxaparin in Liver/Intestine Transplant Recipients
Jackson Memorial Hospital, Miami, FL
*Purpose: Evaluate the use of anti-Xa levels in therapeutic enoxaparin dosing in liver/intestine transplant recipients.*Methods: A single-center retrospective chart review was conducted on liver/intestine transplant…2019 American Transplant Congress
Direct Oral Anticoagulants: An Evaluation of the Safety and Efficacy in Solid Organ Transplant Recipients
Tampa General Hospital, Tampa, FL
*Purpose: The use of direct oral anticoagulants (DOACs) has not been fully adopted by the solid organ transplant (SOT) community due to factors including, fluctuating…2019 American Transplant Congress
The Comparative Safety and Efficacy of Direct Acting Oral Anticoagulants Relative to Warfarin Following Liver Transplantation
Mount Sinai Hospital, New York, NY
*Purpose: This study describes the comparative safety and efficacy of direct acting oral anticoagulants (DOACs) relative to warfarin following liver transplantation, at a large academic…2019 American Transplant Congress
Idarucizumab For The Reversal Of Dabigatran In Patients Undergoing Heart Transplantation
*Purpose: Atrial fibrillation is common among patients with advanced heart failure who are listed for transplantation. Idarucizumab is a monoclonal antibody fragment that was developed…2019 American Transplant Congress
Variables Associated with Intracardiac Thrombus during Orthotopic Liver Transplant: A Retrospective Single-Center Study
*Purpose: Intracardiac thrombus (ICT) is an intraoperative complication during orthotopic liver transplantation (OLT) with high mortality. Patients with end stage liver disease have compromised coagulation…2019 American Transplant Congress
Anticoagulation in Post-Liver Transplant Recipients with Portal Vein Thrombosis
*Purpose: The purpose of this study is to compare safety and efficacy outcomes in liver transplant recipients with portal vein thrombosis (PVT) at the time…2019 American Transplant Congress
Impact of Prolonged Venous Thromboembolism Prophylaxis on 30-Day Hemostatic Outcomes Following Kidney Transplantation in Patients with Hypercoagulable Risk Factors
Mount Sinai Hospital, New York, NY
*Purpose: A number of hypercoagulable states have been identified through laboratory testing that place patients at greater risk for thrombosis; however, the appropriate management of…2019 American Transplant Congress
A Comparison of the Safety and Efficacy of Apixaban Use in Renal Transplant vs. Non-Renal Transplant Recipients
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Background: Utilization of direct-acting oral anticoagulants has become a preferred method for chronic anticoagulation in patients with atrial fibrillation (AF) or venous thromboembolism (VTE).…2019 American Transplant Congress
Novel Oral Anticoagulants in Kidney Transplantation: Results from a Pilote Study
Adult Transplantation, Necker Hospital, Paris, France
*Purpose: Oral anticoagulation therapy is frequently prescribed to kidney transplant recipients, for prevention and treatment of thrombotic events. Over the past ten years, novel oral…
American Transplant Congress abstracts